News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
The company is doubling its chemistry research capacity that should commission by Q2'FY22
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
EPL will supply APR approved 100% recyclable and fully sustainable Platina Tubes for the toothpaste category of Unilever
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Subscribe To Our Newsletter & Stay Updated
